Board tracked Radar started tracking this company’s job board (2 open jobs at last check). source ↗
Trial start Phase 2: Challenge Transfusion of INTERCEPT Pathogen Reduced Red Blood Cells (RBCs) in Subjects With or Without Pre-existing Antibodies to INTERCEPT RBCs source ↗
Trial start —: Cryo-FIRST: Effectiveness of INTERCEPT Fibrinogen Complex (IFC) for Trauma-Associated Hemorrhage source ↗
Trial start Phase 2: A Recovery and Lifespan Study Using INTERCEPT Red Blood Cells Prepared Using the INTERCEPT Blood System for RBCs With AS-1 source ↗
Trial start Phase 2: A Study to Assess Recovery and Survival of Radiolabeled Apheresis Platelet Components Treated With the INTERCEPT Blood System for Platelets With LED Illuminator. source ↗
Trial start Phase 2: In Vivo Study to Assess the Recovery and Survival of Radiolabeled Autologous INTERCEPT Apheresis Platelet Components Suspended in 100% Plasma Stored for up to 7 Days source ↗
Trial start Phase 3: Study to Evaluate the Efficacy & Safety of the INTERCEPT Blood System for RBCs in Complex Cardiac Surgery Patients source ↗
Trial start Phase 3: INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections source ↗
Trial start —: A Open Label, Post Marketing Surveillance Study Following Transfusion of INTERCEPT Platelet Components source ↗
Trial start Phase 2: A Randomized, Multi-center, Open-label, Paired Controlled, Crossover In Vivo Study source ↗
Trial start —: A Prospective, Open Label, Treatment Use Study of Patient Safety Following Transfusion of INTERCEPT Platelet Components source ↗
Trial start 1: A Prospective, Open Label, Phase 1 Safety Study of Passive Immune Therapy During Acute Ebola Virus Disease Using Transfusion of INTERCEPT Plasma Prepared From Volunteer Donors Who Have Recovered Fr source ↗
Trial start Phase 2: A Controlled, In Vivo, Pilot Study to Assess the Recovery and Survival of Radiolabeled Autologous INTERCEPT Treated 7-Day Stored Apheresis Platelet Components in 35% Plasma and 65% InterSol a source ↗
Trial start Phase 3: Study to Assess S303 RBCs and Evaluate Safety and Efficacy in Patients Requiring Transfusion Support of Acute Anemia source ↗
Trial start Phase 3: Study to Evaluate Efficacy and Safety of S303 Treated Red Blood Cells (RBCs)in Subjects With Thalassemia Major Requiring Chronic RBC Transfusion source ↗
Trial start Phase 2: A Study to Assess the Recovery and Lifespan of Radiolabeled Autologous S303 Treated Red Blood Cells source ↗
Trial start Phase 3: Efficacy and Safety Study of Platelets Treated for Pathogen Inactivation and Stored for Up to Seven Days source ↗
Upcoming milestones
Dec 15, 2026 (ESTIMATED) · Phase 2 · A Recovery and Lifespan Study Using INTERCEPT Red Blood Cells Prepared Using the INTERCEPT Blood System for RBCs With AS-1 · NCT07015437
2028-07 (ESTIMATED) · · Cryo-FIRST: Effectiveness of INTERCEPT Fibrinogen Complex (IFC) for Trauma-Associated Hemorrhage · NCT07218185
Sep 30, 2030 (ESTIMATED) · Phase 2 · Challenge Transfusion of INTERCEPT Pathogen Reduced Red Blood Cells (RBCs) in Subjects With or Without Pre-existing Antibodies to INTERCEPT RBCs · NCT07152379
Estimated primary completion per ClinicalTrials.gov. Dates move.
Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.
A Study to Assess Recovery and Survival of Radiolabeled Apheresis Platelet Components Treated With the INTERCEPT Blood System for Platelets With LED Illuminator.
In Vivo Study to Assess the Recovery and Survival of Radiolabeled Autologous INTERCEPT Apheresis Platelet Components Suspended in 100% Plasma Stored for up to 7 Days
A Prospective, Open Label, Phase 1 Safety Study of Passive Immune Therapy During Acute Ebola Virus Disease Using Transfusion of INTERCEPT Plasma Prepared From Volunteer Donors Who Have Recovered From Ebola Virus Disease
A Controlled, In Vivo, Pilot Study to Assess the Recovery and Survival of Radiolabeled Autologous INTERCEPT Treated 7-Day Stored Apheresis Platelet Components in 35% Plasma and 65% InterSol and 7-Day Stored Apheresis Platelet Components in 100% Plasma
Efficacy and Safety Study of Platelets Treated for Pathogen Inactivation and Stored for Up to Seven Days
Phase 3
Completed
2005-10
2009-07 (actual)
NIH awards 41
Annual award amounts. Total $12.2M.
NIH award 5U01AI070834-02 FY2007: $188,270 awarded for that fiscal year; activity U01 (OTHER_NIH); PI DUBENSKY, THOMAS W.; recipient as written: CERUS CORPORATION, CONCORD, CA. Development of Listeria-Based Clinical source ↗
NIH award 5R44CA101421-03 FY2006: $332,770 awarded for that fiscal year; activity R44 (SBIR); PI DUBENSKY, THOMAS W.; recipient as written: CERUS CORPORATION, CONCORD, CA. Listeria Immunotherapy for Pancreatic and Ov source ↗
NIH award 1U01AI070834-01 FY2006: $356,163 awarded for that fiscal year; activity U01 (OTHER_NIH); PI DUBENSKY, THOMAS W.; recipient as written: CERUS CORPORATION, CONCORD, CA. Development of Listeria-Based Clinical source ↗
NIH award 5U01AI061199-03 FY2006: $946,796 awarded for that fiscal year; activity U01 (OTHER_NIH); PI DUBENSKY, THOMAS W.; recipient as written: CERUS CORPORATION, CONCORD, CA. Psoralen-Killed, Metabolically-Active A source ↗
NIH award 5R43CA109868-02 FY2006: $279,813 awarded for that fiscal year; activity R43 (SBIR); PI BROCKSTEDT, DIRK G.; recipient as written: CERUS CORPORATION, CONCORD, CA. Listeria-Based Ovarian Cancer Polyepitope Va source ↗
NIH award 1R41HL083719-01 FY2006: $100,000 awarded for that fiscal year; activity R41 (STTR); PI ROBACK, JOHN D; recipient as written: CERUS CORPORATION, CONCORD, CA. Vaccine-enhanced DLI to prevent cancer recurrence source ↗
NIH award 2R44CA101421-02 FY2005: $503,783 awarded for that fiscal year; activity R44 (SBIR); PI DUBENSKY, THOMAS W.; recipient as written: CERUS CORPORATION, CONCORD, CA. Listeria Immunotherapy for Pancreatic and Ov source ↗
NIH award 5U01AI061199-02 FY2005: $1,174,248 awarded for that fiscal year; activity U01 (OTHER_NIH); PI DUBENSKY, THOMAS W.; recipient as written: CERUS CORPORATION, CONCORD, CA. Psoralen-Killed, Metabolically-Active source ↗
NIH award 1R43CA109868-01A1 FY2005: $279,813 awarded for that fiscal year; activity R43 (SBIR); PI GIEDLIN, MARTIN A; recipient as written: CERUS CORPORATION, CONCORD, CA. Listeria-Based Ovarian Cancer Polyepitope Va source ↗
NIH award 5R44HL074675-03 FY2005: $374,303 awarded for that fiscal year; activity R44 (SBIR); PI CORASH, LAWRENCE; recipient as written: CERUS CORPORATION, CONCORD, CA. Validation of Amotosalen-HCI for Clinical Use source ↗
NIH award 1R42HL076945-01 FY2004: $100,000 awarded for that fiscal year; activity R42 (STTR); PI HEARST, JOHN E; recipient as written: CERUS CORPORATION, CONCORD, CA. Amotosalen PCT of Leukapheresis Units for GvHD Th source ↗
NIH award 1U01AI061199-01 FY2004: $1,461,608 awarded for that fiscal year; activity U01 (OTHER_NIH); PI DUBENSKY, THOMAS W.; recipient as written: CERUS CORPORATION, CONCORD, CA. Psoralen-Killed, Metabolically-Active source ↗
NIH award 1R43CA108026-01 FY2004: $100,000 awarded for that fiscal year; activity R43 (SBIR); PI BROCKSTEDT, DIRK G.; recipient as written: CERUS CORPORATION, CONCORD, CA. Listeria-CEA Vaccine-Infected DC for Cancer source ↗
NIH award 1R43CA106088-01 FY2004: $100,000 awarded for that fiscal year; activity R43 (SBIR); PI HEARST, JOHN E; recipient as written: CERUS CORPORATION, CONCORD, CA. MINIATURIZED INSTRUMENTATION FOR THE HTS OF DNA R source ↗
NIH award 4R44HL074675-02 FY2004: $374,303 awarded for that fiscal year; activity R44 (SBIR); PI CORASH, LAWRENCE; recipient as written: CERUS CORPORATION, CONCORD, CA. Validation of Amotosalen-HCI for Clinical Use source ↗
NIH award 1R43CA103432-01 FY2003: $100,000 awarded for that fiscal year; activity R43 (SBIR); PI HEARST, JOHN E; recipient as written: CERUS CORPORATION, CONCORD, CA. DNA Repair Inhibition and Cancer Therapy source ↗
NIH award 1R44HL074675-01 FY2003: $100,000 awarded for that fiscal year; activity R44 (SBIR); PI HEARST, JOHN E; recipient as written: CERUS CORPORATION, CONCORD, CA. Validation of Amotosalen-HCI for Clinical Use source ↗
NIH award 1R43HL074503-01 FY2003: $100,000 awarded for that fiscal year; activity R43 (SBIR); PI HEARST, JOHN E; recipient as written: CERUS CORPORATION, CONCORD, CA. Stem Cell Transplantation for Hemoglobinopathies source ↗
NIH award 1R43HL074471-01 FY2003: $100,000 awarded for that fiscal year; activity R43 (SBIR); PI HEARST, JOHN E; recipient as written: CERUS CORPORATION, CONCORD, CA. Cord Blood Stem Cell Transplantation, Hemoglobino source ↗
NIH award 1R43CA101421-01 FY2003: $100,000 awarded for that fiscal year; activity R43 (SBIR); PI DUBENSKY, THOMAS W.; recipient as written: CERUS CORPORATION, CONCORD, CA. Listeria-Based Vaccines for Ovarian Cancer T source ↗
NIH award 1R43CA101378-01 FY2003: $100,000 awarded for that fiscal year; activity R43 (SBIR); PI GIEDLIN, MARTIN A; recipient as written: CERUS CORPORATION, CONCORD, CA. Use of Listeria as Colon Cancer Vaccine Adjuva source ↗
NIH award 5R01HL063456-03 FY2001: $258,000 awarded for that fiscal year; activity R01 (OTHER_NIH); PI HEARST, JOHN E; recipient as written: CERUS CORPORATION, CONCORD, CA. STEM CELL TRANSPLANTATION WITH S-59 PHOTOCHE source ↗
NIH award 5R01HL063456-02 FY2000: $258,000 awarded for that fiscal year; activity R01 (OTHER_NIH); PI HEARST, JOHN E; recipient as written: CERUS CORPORATION, CONCORD, CA. STEM CELL TRANSPLANTATION WITH S-59 PHOTOCHE source ↗
NIH award 1R01HL063456-01 FY1999: $258,000 awarded for that fiscal year; activity R01 (OTHER_NIH); PI HEARST, JOHN E; recipient as written: CERUS CORPORATION, CONCORD, CA. STEM CELL TRANSPLANTATION--S-59 PHOTOCHEM T source ↗
NIH award 5R01HL053380-05 FY1998: $455,926 awarded for that fiscal year; activity R01 (OTHER_NIH); PI COOK, DAVID N; recipient as written: CERUS CORPORATION, CONCORD, CA. NOVEL PHENOTHIAZINES FOR DECONTAMINATION OF R source ↗
NIH award 5R01HL053357-05 FY1998: $273,676 awarded for that fiscal year; activity R01 (OTHER_NIH); PI WIESEHAHN, GARY P; recipient as written: CERUS CORPORATION, CONCORD, CA. DECONTAMINATION OF NONCELLULAR THERAPEUTI source ↗
NIH award 5R01HL053380-04 FY1997: $406,064 awarded for that fiscal year; activity R01 (OTHER_NIH); PI COOK, DAVID N; recipient as written: CERUS CORPORATION, CONCORD, CA. NOVEL PHENOTHIAZINES FOR DECONTAMINATION OF R source ↗
NIH award 5R01HL053357-04 FY1997: $263,147 awarded for that fiscal year; activity R01 (OTHER_NIH); PI WIESEHAHN, GARY P; recipient as written: CERUS CORPORATION, CONCORD, CA. DECONTAMINATION OF NONCELLULAR THERAPEUTI source ↗
NIH award 5R01HL053380-03 FY1996: $398,165 awarded for that fiscal year; activity R01 (OTHER_NIH); PI COOK, DAVID N; recipient as written: CERUS CORPORATION, CONCORD, CA. NOVEL PHENOTHIAZINES FOR DECONTAMINATION OF R source ↗
NIH award 5R01HL053357-03 FY1996: $253,028 awarded for that fiscal year; activity R01 (OTHER_NIH); PI WIESEHAHN, GARY P; recipient as written: CERUS CORPORATION, CONCORD, CA. DECONTAMINATION OF NONCELLULAR THERAPEUTI source ↗
